← Eichor
Condition: High Risk Acute Myeloid Leukemia Aml Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Acute Myeloid Leukemia Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Phase 1/Phase 2 · 1 location(s) · Zhujiang Hospital · NCT05270200Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Mye
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT07094750Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06394011HVA vs IA/DA or VA in the Treatment of ND HR-AML
Phase 3 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06810791Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT07238712Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06158828Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06816134Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Phase 2 · 14 location(s) · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias · NCT06668558Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment o
Phase 1 · 2 location(s) · Catherine Bollard · NCT02203903Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07607418SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplas
Phase 1 · 3 location(s) · Dana-Farber Cancer Institute · NCT03113643Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/Phase 2 · 1 location(s) · University of Washington · NCT04797767Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803The Efficacy of Allo-HSCT in ND HR-CBF-AML
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06458244A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518IS-free Treg HaploHCT
Phase 1 · 1 location(s) · Dana-Farber Cancer Institute · NCT04678401Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Phase 1/Phase 2 · 2 location(s) · Benjamin Tomlinson · NCT06129734Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Cord Blood Transplant in Adults With Blood Cancers
Phase 2 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT05884333Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.